Novo Nordisk has thrown a curveball at Pfizer by attempting to outbid the U.S. pharma for obesity biotech Metsera. Until this morning, Pfizer’s acquisition of Metsera had appeared done and…
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the FDA has made things official by placing the…
Boehringer Ingelheim has returned to Kyowa Kirin for a 640 million euro ($743 million) deal for a preclinical program the German pharma hopes will offer a new autoimmune disease option.…
Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases. The asset…
Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye to 118 employees in a workforce reduction that…
As the clinical research industry faces mounting pressures from funding constraints, evolving payer expectations and technological disruption, David Burnham, senior vice president of clinical solutions at Syneos Health, says the…
AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago pharma confirmed to Fierce Biotech. “We have terminated clinical activity around ABBV-303,” the…
Novartis is pulling back the curtain on late-stage Sjögren’s wins, revealing an edge for its investigational monoclonal antibody ianalumab over placebo in both studies. “Clearly, with Sjögren’s having no approved…
Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma will…
Amgen Ventures-backed AAVantgarde Bio has raised $141 million in series B funding that the Italian biotech will use to push its two eye disease gene therapies through the clinic. One…